A phase I/Ib multicenter study has evaluated the MTD, safety, and pharmacokinetics of BEZ235, an oral dual PI3K/mTOR inhibitor, when used as monotherapy or in combination with trastuzumab in patients with advanced solid tumors, including HER2‐positive advanced breast cancer (aBC). The gene discussed is MTOR; the disease is breast cancer.